Oncology Outcomes Report



Overcoming Immunotherapy Challenges


Dr. Gulam A. Manji

Dr. Gulam A. Manji

Pancreatic Cancer: Pathways to Progress

Columbia researchers are conducting preclinical combination immunotherapy studies on genetically engineered mice with pancreatic cancer, which unlike other cancers, in most cases does not respond to mono-immunotherapy. It is thought that the highly immunosuppressive tumor microenvironment within pancreas cancer does not allow immunotherapy to be effective as a single agent.

Their goal is to better understand the mechanisms underlying this strong immunosuppressive tumor microenvironment in the pancreas, and identify unique pancreatic ductal adenocarcinoma (PDAC) subtypes, which may allow immunotherapy to produce a therapeutic benefit. Additionally, by identifying distinct immunosuppressive pathways, personalized combination therapies targeting these pathways could make immunotherapy more effective.

Our goal is two-fold: first - to develop novel immunotherapy and targeted combinations in the laboratory, and second - to translate these findings into clinical trials for pancreas cancer patients with a goal of enrolling a majority of patients seen at Columbia onto these trials. - Dr. Gulam A. Manji

In the first phase of a large seven-arm immunotherapy combination study in mice, the researchers identified an immunotherapy combination that resulted in decreasing the rate of tumor growth and allowed the mice to live longer. This new promising combination is being considered for testing in human pancreas cancer patients in a new clinical trial.

A Novel Clinical Trial Platform

In mid-2017, Columbia became the first site internationally to open and enroll patients onto a new clinical trial design (MORPHEUS), which tests different immunotherapy combinations in pancreatic cancer. The multicenter trial involves testing experimental combinations with an adaptive design platform by F. Hoffmann-La Roche. The approach facilitates the investigation of distinct immunotherapy combinations based on the current understanding of pancreatic cancer biology and immunotherapy. The researchers are hopeful that the study will bring the benefits of cancer immunotherapy to bear on pancreatic cancer and allow for rapid testing of multiple combinations within a single clinical trial.

an abdominal tumor is revealed (yellow) that left a void in the abdominal vasculature

Utilizing the PerkinElmer Quantum FX micro-CT, researchers have many imaging options, enabling them to see, for example, the entire vascular system of a mouse abdomen. In this image, an abdominal tumor is revealed (yellow) that left a void in the abdominal vasculature.


Early Stage Lung Cancer: A Tripartite Treatment Approach

This trial, if early results are confirmed, has the potential to redefine the role of standard cancer therapy from cancerkilling to immune modulation. - Dr. Nasser K. Altorki

In an effort to increase response rates to immunotherapy with single agent immune checkpoint blockade, the emerging trend is to combine two immunotherapy drugs, each blocking a different checkpoint. This combinatorial strategy, though scientifically valid, has been associated with an increase in the side effect profile. Therefore, there is a need to investigate alternative methods that enhance the effects of immunotherapy without a significant increase in side effects. One such approach, currently under investigation by Weill Cornell researchers, is to combine immune checkpoint blockers with low dose radiation – not to kill cancer cells, but rather to reprogram the immune cells within the tumor and produce a more vigorous anti-tumor response.

To this end, they are currently conducting an investigator-initiated, window-of-opportunity clinical trial in patients with early stage lung cancers who would ordinarily be treated with surgery or chemotherapy followed by surgery. In this trial, prior to surgery patients are given a very small dose of radiation combined with the immune checkpoint blockade. Following surgery to remove the tumor, treatment with the immune checkpoint alone is continued for one year. Having access to the tissues before and after surgery makes it possible to examine the tumor for evidence of a cancer-killing immune response and to discover biomarkers that would be useful in future refinements of this approach.

The researchers are cautiously optimistic about the results shown in both animal models and patients with lung cancer. The approach has the potential to be practice changing – since it utilizes radiation at much lower doses than is common practice with much lower frequency of side effects. Their hope is that this will redefine the role of standard anti-cancer treatments such as high-dose radiation therapy used for cancer-killing to low dose immune-modulating radiation. Weill Cornell researchers will also investigate serial measurements of circulating tumor DNA as a real-time marker of response to treatment.

Bladder Cancer: A Bold New World

For some 30 years, there had not been any drugs beyond chemotherapy approved for second-line treatment of bladder cancer. In the last two years, the FDA has approved five immuno-therapeutic agents, yet the challenge to treat bladder cancer remains. Among patients treated with any of these five new drugs, only one out of five will respond. Bringing together experts in precision medicine, immunology, and genitourinary oncology, Weill Cornell’s world-class bladder cancer research program encompasses a multi disciplinary team of physician-scientists who span the basic, translational, and clinical research arenas. The cornerstone of the program is a basic science laboratory, one of the few in the country dedicated to bladder cancer research. It is supported, in part, by a prestigious grant awarded to Bishoy M. Faltas, MD, from the Department of Defense’s Congressionally Directed Medical Research Program, which for the first time has added bladder cancer to its list of fundable areas.

Dr. Faltas is an oncologist in the Genitourinary Oncology Program in the Division of Hematology and Medical Oncology at Weill Cornell. The work of the laboratory focuses on understanding the biology of the disease as the key to progress in identifying the next generation of therapeutic advances for patients with bladder cancer.

One of the research initiatives is focusing on the biology of the APOBEC3 family of proteins. A pattern of mutations ascribed to these proteins was found to be enriched in bladder cancer patients who have had chemotherapy and could be driving resistance to chemotherapy in the advanced stages of bladder cancer. Dr. Faltas is now testing whether these proteins play a role in editing the DNA of bladder cancer cells to cause mutations that drive chemotherapy resistance over time.

Illustration of CCCP using the Illumina HiSeq2500 platform, a sequencing-only test, to query 467 cancer-related genes.

The CCCP uses the Illumina HiSeq2500 platform, a sequencing-only test, to query 467 cancer-related genes.

The hypothesis is that chemotherapy drugs cause breaks to form in double-stranded DNA, exposing single strands of DNA during the repair process. These exposed strands are then bound and mutated by the APOBEC3 proteins in bladder cancer cells. Ongoing studies in the new bladder cancer research program will dissect the mechanisms that drive the evolution of bladder cancer and resistance to therapy with the ultimate goal of translating these results to new treatments for patients.

CAR T-Cell Therapy: Genetically Engineering Attack Cells

Columbia and Weill Cornell researchers have conducted significant foundational work in T-cell-based cancer treatments in the lab and with patients, with the goal of bringing T-cell therapies to patients with a wide range of cancers. Chimeric antigen receptor (CAR) T-cell therapy is one such approach, engaging an individual’s own immune cells to treat cancer, and, in particular, hematological malignancies. In CAR T-cell therapy, T-cells are obtained from the patient and with genetic engineering, these cells are trained to identify, attack, and kill cancer cells. With the first ever FDA approval for a CAR T-cell therapy, (CTL019), in August 2017 for children and young adults with relapsed or refractory β-cell acute lymphoblastic leukemia, interest in this first-in-class therapy has intensified.

NewYork-Presbyterian/Columbia is among the medical centers selected to offer the recently approved CAR T-cell therapy to children and young adults, and several physicians have been trained in understanding the risks associated with infusion of CAR T-cells and how to appropriately manage them. - Dr. Prakash Satwani

Targeting AML

Dr. Gail J. Roboz

Dr. Gail J. Roboz

The first-in-human administration of UCART123 in acute myeloid leukemia (AML) is underway in a phase 1 clinical trial at Weill Cornell Medicine. This marks the first allogeneic, “off-the-shelf” gene-edited CAR T-cell product candidate targeting CD123 to be investigated in clinical trials. The clinical trial will investigate the safety and efficacy of UCART123 in patients with AML, a devastating clonal hematopoietic stem cell neoplasm characterized by uncontrolled proliferation and accumulation of leukemic blasts in bone marrow, peripheral blood and, occasionally, in other tissues. These cells disrupt normal hematopoiesis and rapidly cause bone marrow failure.

While complete response rates can be as high as 80 percent in younger patients who undergo initial induction cytotoxic chemotherapy, the majority of AML patients relapse and die from the disease. AML patients with high-risk genetic features have an especially urgent unmet medical need, as their outcomes are dismal with all existing treatment modalities. Weill Cornell researchers are hopeful that this novel immunotherapy modality will prove to be a significant and effective weapon against AML.

The CAR-modified T-cells are engineered in the laboratory and then infused into a patient. These enhanced cells are designed to recognize and attack stem cells harboring the CD123 antigen, which is present on AML blast and stem cells. - Dr. Gail J. Roboz

Potential for Advanced Thyroid Cancer

In the first demonstration of the potential for CAR T-cell immunotherapy for previously untreatable anaplastic thyroid cancers (ATC), researchers at Weill Cornell were able to eliminate cancerous cells in cultures and mice. Investigators are now hoping to validate their findings in human trials in 2018. Targeting the intercellular adhesion molecule-1 (ICAM-1), which has an increased expression in ATC tumors, Irene M. Min, PhD, Assistant Professor of Molecular Biology Research in Surgery, harvested T-cells from human patients and encoded the cells to seek out ICAM-1 to attack the tumor (Clinical Cancer Research 2017). The researchers found that a single dose on thyroid cancer cells in a mouse model mediated significant tumor killing with a 100-fold reduction in primary tumor burden compared to pre-treatment.

The ICAM-1 CAR T-cells were also injected into mice engrafted with human tumor samples. The tumors were in most cases completely eliminated and the mice thrived, with no significant toxicity, presenting an opportunity for patients with advanced thyroid cancer who have no other options. The researchers noted that high expression of ICAM-1 has also been observed in many other cancers, and linked to metastasis, so the implications of the study could be far reaching. In collaboration with Moonsoo Jin, PhD, Associate Professor in the Department of Radiology, a lower affinity of CAR T-cells to ICAM-1 were developed to make them more selective to cancer cells with limited off-target toxicity (Scientific Reports 2017). The researchers teamed up with Thomas J. Fahey, III, MD, Director of the Endocrine Oncology Program at Weill Cornell, along with hematologists, radiologists, and other clinicians to develop a phase 1 clinical trial.